I’m a former flight attendant. Here are 9 things I wish passengers would stop doing on airplanes

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Financial Intelligence • Markets • World News • Independent Analysis
Published: 2026-10-02 • Permanent link

The US government's surprise move to boost domestic production of generic drugs has sent shockwaves through the global market, with experts predicting a ripple effect on the economy. The Trump administration's decision, announced earlier this week, aims to create 29,000 new jobs and reduce reliance on foreign suppliers. The impact is already being felt, with major pharmaceutical companies like Pfizer and Johnson & Johnson announcing plans to invest heavily in domestic production.

As a result, investors are bracing themselves for a potential downturn in the global pharmaceutical market. The increased competition from domestic producers could lead to a decrease in profits for companies that have historically relied on foreign suppliers. This, in turn, could have a ripple effect on the broader economy, impacting industries that rely on pharmaceuticals for medical treatments and research. The market is already showing signs of unease, with stock prices for pharmaceutical companies experiencing a significant decline.

This seismic shift in the pharmaceutical industry is reminiscent of the 1980s, when the US government introduced the Hatch-Waxman Act, which allowed generic versions of patented drugs to be approved for sale. The move led to a surge in competition, forcing pharmaceutical companies to rethink their business models and invest in research and development. Similarly, the current move is expected to lead to a similar transformation, with companies adapting to the new landscape and investing in domestic production.

As the pharmaceutical industry continues to grapple with the implications of the Trump administration's decision, investors and analysts are left wondering what's next. Will the increased competition lead to lower prices for consumers, or will it result in a decrease in the quality of medicines available? The answer will depend on how the industry responds to the shift, and how the government regulates the new landscape. One thing is certain, however: the pharmaceutical industry will never be the same again.